Company intelligence / Profile preview
Cmxtwenty
Tucson, Arizona, United Statescmxtwenty.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CMX Twenty is a biotechnology company dedicated to developing non-opioid therapeutics for the treatment of chronic pain. Founded by researchers from the University of Arizona, the company focuses on small molecule inhibitors that disrupt the interaction between the Collapsing Response Mediator Protein 2 (CRMP2) and the voltage-gated sodium channel NaV1.7. This novel mechanism aims to provide effective pain relief without the addictive properties or side effects associated with traditional opioids. The company's lead program, CMX-020, has demonstrated potential in preclinical models of neuropathic pain. In early 2023, CMX Twenty was acquired by Eli Lilly to bolster their pain management pipeline.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of Arizona
Beyond the preview
Go deeper on Cmxtwenty.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cmxtwenty.